Stručni rad
Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma
Smiljka Popović-Suić
Borna Šarićić
Puni tekst: hrvatski pdf 332 Kb
str. 66-66
preuzimanja: 567
citiraj
APA 6th Edition
Popović-Suić, S. i Šarićić, B. (2008). Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica, 47 (Supplement 1), 63-66. Preuzeto s https://hrcak.srce.hr/index.php/22769
MLA 8th Edition
Popović-Suić, Smiljka i Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica, vol. 47, br. Supplement 1, 2008, str. 63-66. https://hrcak.srce.hr/index.php/22769. Citirano 03.01.2025.
Chicago 17th Edition
Popović-Suić, Smiljka i Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica 47, br. Supplement 1 (2008): 63-66. https://hrcak.srce.hr/index.php/22769
Harvard
Popović-Suić, S., i Šarićić, B. (2008). 'Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma', Acta clinica Croatica, 47(Supplement 1), str. 63-66. Preuzeto s: https://hrcak.srce.hr/index.php/22769 (Datum pristupa: 03.01.2025.)
Vancouver
Popović-Suić S, Šarićić B. Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica [Internet]. 2008 [pristupljeno 03.01.2025.];47(Supplement 1):63-66. Dostupno na: https://hrcak.srce.hr/index.php/22769
IEEE
S. Popović-Suić i B. Šarićić, "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma", Acta clinica Croatica, vol.47, br. Supplement 1, str. 63-66, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/index.php/22769. [Citirano: 03.01.2025.]
Puni tekst: engleski pdf 332 Kb
str. 63-66
preuzimanja: 435
citiraj
APA 6th Edition
Popović-Suić, S. i Šarićić, B. (2008). Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica, 47 (Supplement 1), 63-66. Preuzeto s https://hrcak.srce.hr/index.php/22769
MLA 8th Edition
Popović-Suić, Smiljka i Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica, vol. 47, br. Supplement 1, 2008, str. 63-66. https://hrcak.srce.hr/index.php/22769. Citirano 03.01.2025.
Chicago 17th Edition
Popović-Suić, Smiljka i Borna Šarićić. "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma." Acta clinica Croatica 47, br. Supplement 1 (2008): 63-66. https://hrcak.srce.hr/index.php/22769
Harvard
Popović-Suić, S., i Šarićić, B. (2008). 'Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma', Acta clinica Croatica, 47(Supplement 1), str. 63-66. Preuzeto s: https://hrcak.srce.hr/index.php/22769 (Datum pristupa: 03.01.2025.)
Vancouver
Popović-Suić S, Šarićić B. Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma. Acta clinica Croatica [Internet]. 2008 [pristupljeno 03.01.2025.];47(Supplement 1):63-66. Dostupno na: https://hrcak.srce.hr/index.php/22769
IEEE
S. Popović-Suić i B. Šarićić, "Early Effects of Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma", Acta clinica Croatica, vol.47, br. Supplement 1, str. 63-66, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/index.php/22769. [Citirano: 03.01.2025.]
Sažetak
The aim of this study was to evaluate early treatment response following intravitreal bevacizumab therapy in 4 patients with neovascular glaucoma. Four patients with neovascular glaucoma and pronounced congestion of anterior chamber received intravitreal bevacizumab injection (1.25 mg/0.05 mL). Intravitreal bevacizumab resulted in marked regression of anterior segment neovascularization documented by fluorescein angiography and iridography, and relief of symptoms within 24 hours. Cyclocryocoagulation was carried out only if pressure was insufficiently controlled by topical therapy. Follow up examination was performed at 1 month. In conclusion, intravitreal bevacizumab leads to rapid regression of iris and angle neovacularization in the early period of observation. Controlled randomized trial is needed to test whether intraocular injections of bevacizumab provide long term benefit to patients with neovascular glaucoma.
Ključne riječi
Neovascular glaucoma; Bevacizumab
Hrčak ID:
22769
URI
https://hrcak.srce.hr/22769
Datum izdavanja:
1.4.2008.
Podaci na drugim jezicima:
hrvatski
Posjeta: 2.116
*
